^
    22h
    Phase II Randomized-registry Embedded Study of Lymphoscintigraphy for Oropharyngeal Neoplasms to Enable Risk-adapted Nodal Guidance for Robotic Surgery and/or Radiotherapy (LONE-RANGR2) (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=240 --> 8
    Enrollment closed • Enrollment change
    23h
    Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)" (clinicaltrials.gov)
    P2, N=63, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin
    5d
    NCI-2021-13901: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (clinicaltrials.gov)
    P1, N=46, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jul 2027 | Trial primary completion date: Jun 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • ipatasertib (RG7440)
    5d
    NimoBenSeq: Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: A Randomized Controlled Trial (clinicaltrials.gov)
    P2/3, N=386, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Andewei (benmelstobart) • TheraCIM (nimotuzumab)
    5d
    Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=370, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    cisplatin • bemcentinib (BGB324) • Andewei (benmelstobart) • TheraCIM (nimotuzumab)
    6d
    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design (clinicaltrials.gov)
    P2, N=120, Recruiting, Christopher Wilke | Trial completion date: Dec 2030 --> Dec 2031 | Trial primary completion date: Dec 2030 --> Dec 2031
    Trial completion date • Trial primary completion date
    |
    ERCC1 (Excision repair cross-complementation group 1)
    |
    Erbitux (cetuximab) • cisplatin • docetaxel
    6d
    Biomarkers & Survival in Head and Neck Squamous Cell Carcinoma: A Systematic Review & Meta-Analysis. (PubMed, OTO Open)
    These findings support EGFR, cyclin D1, and Bcl-2 as biomarkers which portend worse prognosis in HNSCC. Further work will be needed to understand whether measurement of these proteins can be useful in tailoring treatment strategies, and whether they can be used as targets for novel therapies.
    Retrospective data • Review • Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1)
    7d
    HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (clinicaltrials.gov)
    P1, N=32, Completed, Baylor College of Medicine | Active, not recruiting --> Completed | Trial completion date: Oct 2033 --> Jan 2026
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV
    7d
    ECLIPSE: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases (clinicaltrials.gov)
    P3, N=412, Recruiting, Rakuten Medical, Inc.
    New P3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • Akalux (cetuximab sarotalocan)
    8d
    NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P1/2, N=121, Active, not recruiting, Novita Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    NP-G2-044
    8d
    A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Mayo Clinic | Completed --> Active, not recruiting | Trial completion date: Apr 2025 --> Sep 2026
    Enrollment closed • Trial completion date
    |
    Keytruda (pembrolizumab) • Versamune HPV
    8d
    Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) (clinicaltrials.gov)
    P=N/A, N=72, Completed, Travera Inc | Recruiting --> Completed | N=200 --> 72 | Trial completion date: Jul 2028 --> Mar 2026 | Trial primary completion date: Jul 2027 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date